Biotech

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
Stock Of The Day: Is Pfizer Set Up To Rally?
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Stock Of The Day: Is Pfizer Set Up To Rally?
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Robert Kennedy Jr. Poised To Lead Health And Human Services: Why FDA, NIH Officials Are Nervous

Biotech Recent News

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety.
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
Eyenovia's Phase 3 CHAPERONE study fails to meet its primary endpoint, prompting a review of strategic alternatives, including potential mergers or asset sales.
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention.
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis.
Selling Weed Is Like A Sneaker Drop: Running Out Isn't A Problem For This Company
As the industry consolidates scooping up smaller players, Garden Greens stands out with a fashion-to-weed approach and street-smart pricing.
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved